Form 4: Zoetis EVP Polzer Reports Future Phantom Stock Grant

Zoetis Executive Vice President Robert J. Polzer reported the acquisition of 204.6185 phantom stock units, effective October 10, 2025, under a Rule 10b5-1 plan.

Summary

• Robert J. Polzer, Executive Vice President of Zoetis Inc., reported the acquisition of 204.6185 Phantom Stock Units.
• The transaction date for this acquisition is October 10, 2025.
• These phantom stock units were acquired pursuant to the Zoetis Supplemental Savings Plan.
• Phantom stock units are settled in cash following the reporting person's separation from service.
• The value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and approximately 5% cash-equivalent investments.
• Following this reported transaction, Polzer beneficially owns 10,990.0773 phantom stock units.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: This is a routine disclosure of executive compensation, neither inherently positive nor negative for the company's immediate prospects. It reflects standard incentive practices.

Positives

• The acquisition of phantom stock units aligns executive interests with shareholder value, as the units' value is tied to Zoetis common stock performance.
• The transaction being part of a Rule 10b5-1 plan indicates a structured and pre-planned compensation event, reflecting stable corporate governance practices.

Future Outlook

The transaction date of October 10, 2025, indicates a pre-planned compensation event scheduled to occur in the future, reflecting ongoing executive incentive programs.

Industry Context

This is a routine executive compensation disclosure, common across various industries, particularly in large pharmaceutical and animal health sectors, to incentivize and retain key management personnel through equity-linked awards.

Comparison to Industry Standards

• Phantom stock units are a common form of executive compensation, often used in supplemental savings plans to defer income and align long-term interests.
• Companies like Pfizer (from which Zoetis was spun off) and other large pharmaceutical and animal health companies, such as Elanco Animal Health (ELAN) or Merck Animal Health (part of MRK), utilize similar equity-based compensation structures to incentivize executives and link their performance to shareholder value.

Related Party Transactions

• Acquisition of 204.6185 phantom stock units by Executive Vice President Robert J. Polzer as part of the Zoetis Supplemental Savings Plan.

Stakeholder Impact

• Shareholders: Minor positive impact due to continued alignment of executive interests with company performance through equity-linked compensation.
• Employees: No direct impact mentioned for the broader employee base.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned acquisition of phantom stock units by an executive as part of a compensation plan. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates ongoing executive alignment with shareholder interests through equity-based compensation, which is a neutral factor for immediate stock price movement.

Keywords

Zoetis, ZTS, Form 4, Insider Transaction, Phantom Stock, Executive Compensation, Robert J. Polzer, 10b5-1 Plan